2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2635

Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus
Abstract Number: 693

Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Abstract Number: 863

Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension
Abstract Number: 694

Combining Etanercept with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Abstract Number: 604

Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Abstract Number: 572

Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®
Abstract Number: 1089

Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms
Abstract Number: PP08

Communication, Support, and Advocacy Lead to Improved Health and Quality of Life
Abstract Number: 2838

Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database
Abstract Number: 2768

Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Abstract Number: 1565

Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
Abstract Number: 581

Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
Abstract Number: 1098

Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
Abstract Number: 1174

Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
Abstract Number: 2133

Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].